STOCK TITAN

Tekla Healthcare Opportunities Fund Declares Monthly Cash Distribution

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Tekla Healthcare Opportunities Fund (THQ) has declared a monthly cash distribution of $0.1125 per share. The record date for the distribution is July 20, 2023, and the payable date is July 31, 2023. Only participants in the Fund's Dividend Reinvestment and Stock Purchase Plan will have cash distributions automatically reinvested in shares.
Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- On July 10, 2023, Tekla Healthcare Opportunities Fund declared its monthly cash distribution of $0.1125 per share. The record date for the monthly cash distribution is July 20, 2023 and the payable date is July 31, 2023. The Fund will trade ex-distribution on July 19, 2023.

Note that only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan (“DRIP”) will have cash distributions automatically reinvested in shares of the Fund.

Tekla Healthcare Opportunities Fund (NYSE: THQ) is a closed-end fund that invests in companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Please contact Destra Capital Advisors, the Fund’s marketing and investor support services agent, at THQ@destracapital.com or call (877) 855-3434 if you have any questions regarding THQ.

Destra Capital Advisors

THQ@destracapital.com

(877) 855-3434

Source: Tekla Healthcare Opportunities Fund

FAQ

What is the monthly cash distribution declared by Tekla Healthcare Opportunities Fund?

Tekla Healthcare Opportunities Fund has declared a monthly cash distribution of $0.1125 per share.

When is the record date for the monthly cash distribution?

The record date for the monthly cash distribution is July 20, 2023.

When is the payable date for the monthly cash distribution?

The payable date for the monthly cash distribution is July 31, 2023.

Who will have cash distributions automatically reinvested in shares?

Only participants in the Fund's Dividend Reinvestment and Stock Purchase Plan will have cash distributions automatically reinvested in shares.

Where can shares of Tekla Healthcare Opportunities Fund be purchased?

Shares of Tekla Healthcare Opportunities Fund can be purchased on the New York Stock Exchange through any securities broker.

Who serves as the Investment Adviser to Tekla Healthcare Opportunities Fund?

Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to Tekla Healthcare Opportunities Fund.

How can I contact Destra Capital Advisors?

You can contact Destra Capital Advisors, the Fund's marketing and investor support services agent, at THQ@destracapital.com or call (877) 855-3434.

Where can I find more information about Tekla Healthcare Opportunities Fund and Tekla Capital Management LLC?

You can find more information about Tekla Healthcare Opportunities Fund and Tekla Capital Management LLC at www.teklacap.com.

abrdn Healthcare Opportunities Fund

NYSE:THQ

THQ Rankings

THQ Latest News

THQ Stock Data

818.85M
41.34M
0%
20.76%
0.04%
Asset Management
Financial Services
Link
United States of America
Boston

About THQ

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form